PDF herunterladen
Semin Liver Dis 2003; 23(1): 047-058
DOI: 10.1055/s-2003-37590
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Natural History and Prognosis of Hepatitis B

Giovanna Fattovich
  • Professor of Medicine, Servizio Autonomo Clinicizzato di Gastroenterologia, University of Verona, Verona, Italy
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. März 2003 (online)

    Lizenzen und Reprints

ABSTRACT

The natural history of hepatitis B virus (HBV) infection is complex and variable and is greatly influenced by the age at infection, the level of HBV replication, and host immune status. Chronic HBV infection generally consists of an early replicative phase with active liver disease (hepatitis B e antigen [HBeAg]-positive chronic hepatitis) and a late low or nonreplicative phase with HBeAg seroconversion and remission of liver disease (inactive carrier state). After HBeAg seroconversion, some patients may have active hepatitis due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Morbidity and mortality are linked to development of cirrhosis and hepatocellular carcinoma. Survival is reasonably good (about 85% probability at 5 years) in compensated cirrhosis but very poor in decompensated cirrhosis. Both cirrhotic and noncirrhotic patients with sustained reduction of HBV replication and normalization of aminotransferase after interferon alfa therapy have a reduced risk for liver-related complications.

KEYWORDS

Hepatitis B virus - chronic hepatitis B - interferon alfa

REFERENCES

  • 1 Maddrey W C. Hepatitis B: an important public health issue.  J Med Virol . 2000;  61 362-366
    CrossrefPubMedSuche in Google Scholar
  • 2 Lee W M. Hepatitis B virus infection.  N Engl J Med . 1997;  337 1733-1745
    CrossrefPubMedSuche in Google Scholar
  • 3 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000-summary of a workshop.  Gastroenterology . 2001;  120 1828-1853
    PubMedSuche in Google Scholar
  • 4 Lok A SF, McMahon B J. Chronic hepatitis B.  Hepatology . 2001;  34 1225-1241
    CrossrefPubMedSuche in Google Scholar
  • 5 Milich D R, Chen M K, Hughes J L, Jones J E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence.  J Immunol . 1998;  160 2013-2021
    PubMedSuche in Google Scholar
  • 6 Hadziyannis S J, Vassilopoulos D. Hepatitis B e antigen- negative chronic hepatitis B.  Hepatology . 2001;  34 617-624
    CrossrefPubMedSuche in Google Scholar
  • 7 Chemin I, Zoulim F, Merle P. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology.  J Hepatol . 2001;  34 471-473
    CrossrefPubMedSuche in Google Scholar
  • 8 Kawatani T, Suou T, Tajima F. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.  Eur J Haematol . 2001;  67 45-50
    CrossrefPubMedSuche in Google Scholar
  • 9 McMahon B J, Alward W LM, Hall D B. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.  J Infect Dis . 1985;  151 599-603
    PubMedSuche in Google Scholar
  • 10 Smedile A, Farci P, Verme G. Influence of delta infection on severity of hepatitis B.  Lancet . 1982;  2 945-947
    PubMedSuche in Google Scholar
  • 11 Feray C, Gigou M, Samuel D. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis.  Gastroenterology . 1993;  104 549-555
    PubMedSuche in Google Scholar
  • 12 Chang M H. Natural history of hepatitis B infection in children.  J Gastroenterol Hepatol . 2000;  15(Suppl) E11-E19
    CrossrefPubMedSuche in Google Scholar
  • 13 Tassopoulos N C, Papaevangelou G J, Sjogren M H. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults.  Gastroenterology . 1987;  92 1844-1850
    PubMedSuche in Google Scholar
  • 14 Burk R D, Hwang L Y, Ho G YF, Shafritz D A, Beasley R P. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load.  J Infect Dis . 1994;  170 1418-1423
    CrossrefPubMedSuche in Google Scholar
  • 15 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.  J Hepatol . 2002;  36 426-432
    CrossrefPubMedSuche in Google Scholar
  • 16 Lok A SF, Lai C L, Wu P C, Leung E KY, Lam T S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection.  Gastroenterology . 1987;  92 1839-1843
    PubMedSuche in Google Scholar
  • 17 Realdi G, Alberti A, Rugge M. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection.  Gastroenterology . 1980;  79 195-199
    PubMedSuche in Google Scholar
  • 18 Hoofnagle J H, Dusheiko G M, Seef L B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis.  Ann Intern Med . 1981;  94 744-748
    PubMedSuche in Google Scholar
  • 19 Fattovich G, Rugge M, Brollo L. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B.  Hepatology . 1986;  6 167-172
    PubMedSuche in Google Scholar
  • 20 Liaw Y F, Tai D I, Chu C M, Chen T J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Hepatology . 1988;  8 493-496
    PubMedSuche in Google Scholar
  • 21 Moreno-Otero R, Garcia-Monzòn C, Garcia-Sànchez A. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients.  Am J Gastroenterol . 1991;  86 560-564
    PubMedSuche in Google Scholar
  • 22 Zarski J P, Marcellin P, Cohard M. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France.  J Hepatol . 1994;  20 636-640
    CrossrefPubMedSuche in Google Scholar
  • 23 Di Marco V, Lo Iacono O, Cammà C. The long-term course of chronic hepatitis B.  Hepatology . 1999;  30 257-264
    CrossrefPubMedSuche in Google Scholar
  • 24 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  29 971-975
    CrossrefPubMedSuche in Google Scholar
  • 25 Yuen M F, Hui C K, Cheng C C. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.  Hepatology . 2001;  34 139-145
    CrossrefPubMedSuche in Google Scholar
  • 26 Chang M H, Hsu H Y, Hsu H C. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.  Hepatology . 1995;  22 1387-1392
    CrossrefPubMedSuche in Google Scholar
  • 27 Bortolotti F, Jara P, Crivellaro C. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.  J Hepatol . 1998;  29 184-190
    CrossrefPubMedSuche in Google Scholar
  • 28 Hsu Y S, Chien R N, Yeh C T. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology . 2002;  35 1522-1527
    CrossrefPubMedSuche in Google Scholar
  • 29 Fong T L, Di Bisceglie M A, Gerber M A, Waggoner J G, Hoofnagle J H. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B.  Hepatology . 1993;  18 1313-1318
    CrossrefPubMedSuche in Google Scholar
  • 30 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus.  Ann Intern Med . 2001;  135 759-768
    CrossrefPubMedSuche in Google Scholar
  • 31 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.  Gastroenterology . 1990;  99 805-810
    PubMedSuche in Google Scholar
  • 32 Wong D KH, Cheung A M, O'Rourke K. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.  Ann Intern Med . 1993;  119 312-323
    PubMedSuche in Google Scholar
  • 33 Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B.  Acta Gastroenterol Belg . 1998;  61 219-223
    PubMedSuche in Google Scholar
  • 34 Chang M H, Sung J L, Lee C Y. Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children.  J Pediatr . 1989;  115 385-390
    PubMedSuche in Google Scholar
  • 35 Alward W LM, McMahon B J, Hall D B. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma.  J Infect Dis . 1985;  151 604-609
    PubMedSuche in Google Scholar
  • 36 Liaw Y F. Current trends in therapy for chronic viral hepatitis.  J Gastroenterol Hepatol . 1997;  12 S346-S353
    PubMedSuche in Google Scholar
  • 37 Perillo R P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.  Gastroenterology . 2001;  120 1009-1022
    CrossrefPubMedSuche in Google Scholar
  • 38 Orito E, Mizokami M, Sakugawa H. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group.  Hepatology . 2001;  33 218-223
    CrossrefPubMedSuche in Google Scholar
  • 39 Chu C J, Hussain M, Lok A SF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C.  Gastroenterology . 2002;  122 1756-1762
    CrossrefPubMedSuche in Google Scholar
  • 40 Chan H LY, Leung N WY, Hussain M, Wong M L, Lok A SF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.  Hepatology . 2000;  31 763-768
    CrossrefPubMedSuche in Google Scholar
  • 41 Funk M L, Rosenberg D M, Lok A SF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.  J Viral Hepat . 2002;  9 52-61
    CrossrefPubMedSuche in Google Scholar
  • 42 Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine.  J Med Virol . 2000;  61 398-402
    CrossrefPubMedSuche in Google Scholar
  • 43 Fattovich G, Farci P, Rugge M. Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen.  Hepatology . 1992;  15 584-589
    PubMedSuche in Google Scholar
  • 44 Lampertico P, Del Ninno E, Manzin A. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.  Hepatology . 1997;  26 1621-1625
    PubMedSuche in Google Scholar
  • 45 Tassopoulos N C, Volpes R, Pastore G. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Group.  Hepatology . 1999;  29 889-896
    CrossrefPubMedSuche in Google Scholar
  • 46 Brunetto M R, Oliveri F, Coco B. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.  J Hepatol . 2002;  36 263-270
    PubMedSuche in Google Scholar
  • 47 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol . 2001;  34 306-313
    CrossrefPubMedSuche in Google Scholar
  • 48 De Franchis R, Meucci G, Vecchi M. The natural history of asymptomatic hepatitis B surface antigen carriers.  Ann Intern Med . 1993;  118 191-194
    PubMedSuche in Google Scholar
  • 49 Bellentani S, Dal Molin G, Miglioli L. Natural history of HBV infection: a 9 years follow-up of the Dionysos cohort.  J Hepatol . 2002;  36(Suppl 1) 228
    PubMedSuche in Google Scholar
  • 50 Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S W. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa.  Hepatology . 1997;  26 1338-1342
    CrossrefPubMedSuche in Google Scholar
  • 51 Fattovich G, Giustina G, Sanchez-Tapias J. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis.  Am J Gastroenterol . 1998;  93 896-900
    CrossrefPubMedSuche in Google Scholar
  • 52 McMahon B J, Alberts S R, Wainwright R B, Bulkow L, Lanier A P. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska Native carriers.  Arch Intern Med . 1990;  150 1051-1054
    CrossrefPubMedSuche in Google Scholar
  • 53 Huo T I, Wu J C, Lee P C. Sero-clearance of hepatitis B surface antigen in chronic carriers not necessarily implies a good prognosis.  Hepatology . 1998;  28 231-236
    CrossrefPubMedSuche in Google Scholar
  • 54 Fattovich G, Brollo L, Giustina G. Natural history and prognostic factors of chronic hepatitis type B.  Gut . 1991;  32 294-298
    PubMedSuche in Google Scholar
  • 55 Ikeda K, Saitoh S, Suzuki Y. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients.  J Hepatol . 1998;  28 930-938
    CrossrefPubMedSuche in Google Scholar
  • 56 Mazzella G, Saracco G, Festi D. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial.  Am J Gastroenterol . 1999;  94 2246-2250
    CrossrefPubMedSuche in Google Scholar
  • 57 Fattovich G, Brollo L, Alberti A. Long term follow-up of anti-HBe positive chronic active hepatitis B.  Hepatology . 1988;  8 1651-1654
    PubMedSuche in Google Scholar
  • 58 Brunetto M R, Oliveri F, Rocca G. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen.  Hepatology . 1989;  10 198-202
    PubMedSuche in Google Scholar
  • 59 Kao J H, Chen P J, Lai M Y, Chen D S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.  Gastroenterology . 2000;  118 554-559
    CrossrefPubMedSuche in Google Scholar
  • 60 Chan H L, Tsang S W, Liew C T. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection.  Am J Gastroenterol . 2002;  97 406-412
    CrossrefPubMedSuche in Google Scholar
  • 61 Fattovich G, Tagger A, Brollo L. A Hepatitis C virus infection in chronic hepatitis B virus carriers.  J Infect Dis . 1991;  163 400-402
    PubMedSuche in Google Scholar
  • 62 Fong T L, Di Bisceglie M A, Waggoner J G, Banks S M, Hoofnagle J H. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.  Hepatology . 1991;  14 64-67
    PubMedSuche in Google Scholar
  • 63 Sagnelli E, Coppola N, Scolastico C. Virologic and clinical expression of reciprocal inhibitory effect of hepatitis B, C and delta viruses in patients with chronic hepatitis.  Hepatology . 2000;  32 1106-1110
    CrossrefPubMedSuche in Google Scholar
  • 64 Gaeta G B, Stroffolini T, Chiaramonte M. Chronic hepatitis D: a vanishing disease?.  <~>An Italian multicenter study. Hepatology . 2000;  32 824-827
    CrossrefPubMedSuche in Google Scholar
  • 65 Fattovich G, Boscaro S, Noventa F. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.  J Infect Dis . 1987;  155 931-935
    CrossrefPubMedSuche in Google Scholar
  • 66 Rosina F, Conoscitore P, Cuppone R. Changing pattern of chronic hepatitis D in Southern Europe.  Gastroenterology . 1999;  117 161-166
    CrossrefPubMedSuche in Google Scholar
  • 67 Colin J F, Cazals-Hatem D, Loriot M A. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.  Hepatology . 1999;  29 1306-1310
    CrossrefPubMedSuche in Google Scholar
  • 68 Liaw Y F, Lin D Y, Chen T J, Chu C M. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.  Liver . 1989;  9 235-241
    PubMedSuche in Google Scholar
  • 69 Kato Y, Nakata K, Omagari K. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses.  Cancer . 1994;  74 2234-2238
    PubMedSuche in Google Scholar
  • 70 Mazzella G, Accogli E, Sottili S. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.  J Hepatol . 1996;  24 141-147
    CrossrefPubMedSuche in Google Scholar
  • 71 Ikeda K, Saitoh S, Suzuki Y. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus.  Cancer . 1998;  82 827-835
    CrossrefPubMedSuche in Google Scholar
  • 72 Fattovich G, Giustina G, Christensen E. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B.  Gut . 2000;  46 420-426
    CrossrefPubMedSuche in Google Scholar
  • 73 Realdi G, Fattovich G, Hadziyannis S. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study.  J Hepatol . 1994;  21 656-666
    CrossrefPubMedSuche in Google Scholar
  • 74 Beasley R P. Hepatitis B virus. The major etiology of hepatocellular carcinoma.  Cancer . 1988;  61 1942-1956
    PubMedSuche in Google Scholar
  • 75 Yu M W, Hsu F C, Sheen I S. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers.  Am J Epidemiol . 1997;  145 1039-1047
    PubMedSuche in Google Scholar
  • 76 McMahon B J, Bulkow L, Harpster A. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population based study.  Hepatology . 2000;  32 842-846
    CrossrefPubMedSuche in Google Scholar
  • 77 Liaw Y F, Tai D I, Chu C M. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study.  Gastroenterology . 1985;  90 263-267
    PubMedSuche in Google Scholar
  • 78 Oon C J. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions.  Cancer Chemother Pharmacol . 1992;  31(Suppl 1) S137-S142
    CrossrefPubMedSuche in Google Scholar
  • 79 Fattovich G, Pantalena M, Zagni I. Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients.  Am J Gastroenterol . 2002;  97 2886-2895
    CrossrefPubMedSuche in Google Scholar
  • 80 Fattovich G, Giustina G, Schalm S W. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B.  Hepatology . 1995;  21 77-82
    CrossrefPubMedSuche in Google Scholar
  • 81 Benvegnù L, Fattovich G, Noventa F. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis.  Cancer . 1994;  74 2442-2448
    CrossrefPubMedSuche in Google Scholar
  • 82 Chung H T, Lai C L, Lok A S. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis.  Hepatology . 1995;  22 25-29
    CrossrefPubMedSuche in Google Scholar
  • 83 De Jongh E F, Janssen H LA, De Man A R. M.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology . 1992;  103 1630-1635
    PubMedSuche in Google Scholar
  • 84 Hui A Y, Chan H L, Leung N W. Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation.  J Clin Gastroenterol . 2002;  34 569-572
    CrossrefPubMedSuche in Google Scholar
  • 85 Hoofnagle J H, Di Bisceglie M A. The treatment of chronic viral hepatitis.  N Engl J Med . 1997;  336 347-356
    PubMedSuche in Google Scholar
  • 86 Evans A A, Fine M, London W T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy.  J Infect Dis . 1997;  176 845-850
    PubMedSuche in Google Scholar
  • 87 Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.  Gastroenterology . 2001;  121 101-109
    CrossrefPubMedSuche in Google Scholar
  • 88 Lampertico P, Viganò M, Iavarone M, Del Ninno E, Colombo M. Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa.  J Hepatol . 2001;  34(Suppl 1) 149
    PubMedSuche in Google Scholar
  • 89 Niederau C, Heintges T, Lange S. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med . 1996;  334 1422-1427
    CrossrefPubMedSuche in Google Scholar
  • 90 EUROHEP: European Concerted Action on HBV-related Cirrhosis 2003. Updated analysis, data on file: Fattovich et al50
  • 91 International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study.  Lancet . 1998;  351 1535-1539
    CrossrefPubMedSuche in Google Scholar
  • 92 Lau D TY, Everhart J, Kleiner D E. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.  Gastroenterology . 1997;  113 1660-1667
    PubMedSuche in Google Scholar
  • 93 Yao F Y, Terrault N A, Freise C, Maslow L, Bass N M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.  Hepatology . 2001;  34 411-416
    CrossrefPubMedSuche in Google Scholar
  • 94 Mutimer D. Beneficial effect of lamivudine for hepatitis B transplant recipients.  Liver Transp . 2002;  8 440-442
    PubMedSuche in Google Scholar